Nedosiran
ALIMENTARY TRACT AND METABOLISM
Also known as: nedosiran sodium, rivfloza
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Nedosiran is a drug catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 3 molecular targets, including LDHA, ASGR1 and ASGR2. Recorded indications include Primary hyperoxaluria, type I.
- Molecular targets: LDHA, ASGR1 and ASGR2 (3 listed in DrugCentral).
- Indications: Primary hyperoxaluria, type I.
- ATC code: A16AX25 (Various alimentary tract and metabolism products).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Primary hyperoxaluria, type I
Mechanism & targets
Molecular targets (3)
| Target | Gene | Action | Activity |
|---|---|---|---|
| L-lactate dehydrogenase A chain mRNA | LDHA | other | — |
| Asialoglycoprotein receptor 1 | ASGR1 | other | — |
| Asialoglycoprotein receptor 2 | ASGR2 | other | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2023-09-29 | FDA | — | NOVO NORDISK INC | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A16AX25 | ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Various alimentary tract and metabolism products |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: AGXT
- FDA label: AGXT
- HCSC label: AGXT
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Nedosiran used for?
DrugCentral lists the following indications for Nedosiran: Primary hyperoxaluria, type I.
How does Nedosiran work?
Its molecular targets in DrugCentral include LDHA, ASGR1 and ASGR2.
When was Nedosiran first approved?
Nedosiran was first approved by the FDA in 2023.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5746 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4594338 — compound record and bioactivity
- FDA UNII 13U9R5J3WL — substance identity
- DailyMed: FDA labels for Nedosiran — current prescribing information (label search)
- UniProt P00338 (LDHA) — target protein
- UniProt P07306 (ASGR1) — target protein
- UniProt P07307 (ASGR2) — target protein
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.